Molecular imaging enables non-invasive monitoring of tumor growth, progression, and drug treatment response, and it has become an important tool to promote biological studies in recent years. In this study, we comprehensively evaluated the in vivo anti-angiogenic and anti-neoplastic effects of Endostar on liver cancer based on the optical molecular imaging systems including micro-computer tomography (Micro-CT), bioluminescence molecular imaging (BLI) and fluorescence molecular tomography (FMT). Firefly luciferase (fLuc) and green fluorescent protein (GFP) dual labeled human hepatocellular carcinoma cells (HCC-LM3-fLuc-GFP cells) were used to establish the subcutaneous and orthotopic liver tumor model. After the tumor cells were implanted 14~18 days, Endostar (5 mg/kg/day) was administered through an intravenous tail vein injection for continuous 14 days. The computer tomography angiography (CTA) and BLI were carried out for the subcutaneous tumor model. FMT was executed for the orthotopic tumor model. The CTA data showed that tumor vessel formation and the peritumoral vasculature of subcutaneous tumor in the Endostar treatment group was significantly inhibited compared to the control group. The BLI data exhibited the obvious tumor inhibition day 8 post-treatment. The FMT detected the tumor suppression effects of Endostar as early as day 4 post-treatment and measured the tumor location. The above data confirmed the effects of Endostar on anti-angiogenesis and tumor suppression on liver cancer. Our system combined CTA, BLI, and FMT to offer more comprehensive information about the effects of Endostar on the suppression of vessel and tumor formation. Optical molecular imaging system enabled the non-invasive and reliable assessment of anti-tumor drug efficacy on liver cancer.
References
[1]
Jemal A, Bray F (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA: a cancer journal for clinicians 61: 69–90.
[2]
Liu L, Cao Y, Chen C, Zhang X, McNabola A, et al. (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851–11858.
[3]
Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5–S16.
[4]
Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15–18.
[5]
Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nature medicine 17: 1359–1370.
Tam K (2013) The Roles of Doxorubicin in Hepatocellular Carcinoma. ADMET & DMPK 1: 29–44.
[8]
Folkman J (2006) Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin. Sci STKE DOI:10.1126/stke.3542006pe35.
[9]
Folkman J (2006) Antiangiogenesis in cancer therapy–endostatin and its mechanisms of action. Exp Cell Res 312: 594–607.
[10]
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277–285.
[11]
Ling Y, Lu N, Gao Y, Chen Y, Wang S, et al. (2009) Endostar induces apoptotic effects in HUVECs through activation of caspase-3 and decrease of Bcl-2. Anticancer Res 29: 411–417.
[12]
Dong X, Zhao X, Xiao T, Tian H, Yun C (2011) Endostar, a recombined humanized endostatin, inhibits lymphangiogenesis and lymphatic metastasis of Lewis lung carcinoma xenograft in mice. Thorac Cardiovasc Surg 59: 133–136.
[13]
Xu W, Ye P, Li Z, Shi J, Wang W, et al. (2010) Endostar, a recently introduced recombinant human endostatin, inhibits proliferation and migration through regulating growth factors, adhesion factors and inflammatory mediators in choroid-retinal endothelial cells. Molecular Biology 44: 585–590.
[14]
Folkman J (2006) Antiangiogenesis in cancer therapy–endostatin and its mechanisms of action. Experimental cell research 312: 594–607.
[15]
Cai W, Gambhir SS, Chen X (2008) Chapter 7. Molecular imaging of tumor vasculature. Methods Enzymol 445: 141–176.
[16]
Cai W, Chen X (2008) Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 49 Suppl 2113S–128S.
[17]
Willmann JK, Van Bruggen N, Dinkelborg LM, Gambhir SS (2008) Molecular imaging in drug development. Nature Reviews Drug Discovery 7: 591–607.
[18]
Jaffer FA, Libby P, Weissleder R (2009) Optical and multimodality molecular imaging insights into atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology 29: 1017–1024.
[19]
Baker M (2010) Whole-animal imaging: The whole picture. Nature 463: 977–980.
[20]
Tian J, Bai J, Bao S (2013) Optical Multi-Modality Molecular Imaging. Molecular Imaging: Springer. pp. 389–414.
[21]
Bibby M (2004) Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. European Journal of Cancer 40: 852–857.
[22]
Avella DM, Li G, Schell TD, Liu D, Zhang SS, et al. (2012) Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology 55: 141–152.
[23]
Feng YX, Wang T, Deng YZ, Yang P, Li JJ, et al. (2011) Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 53: 483–492.
[24]
Blow N (2009) In vivo molecular imaging: the inside job. Nature Methods 6: 465–469.
[25]
Ma X, Tian J, Yang X, Qin C, Zhu S, et al. (2011) Research on liver tumor proliferation and angiogenesis based on multi-modality molecular imaging. Acta Biophys Sin 27: 355–364.
[26]
Zhu S, Tian J, Yan G, Qin C, Feng J (2009) Cone beam micro-CT system for small animal imaging and performance evaluation. Journal of Biomedical Imaging DOI:10.1155/2009/960573.
[27]
Tian J, Xue J, Dai Y, Chen J, Zheng J (2008) A novel software platform for medical image processing and analyzing. Information Technology in Biomedicine, IEEE Transactions on 12: 800–812.
[28]
Xue Z, Ma X, Zhang Q, Wu P, Yang X, et al. (2013) Adaptive regularized method based on homotopy for sparse fluorescence tomography. Appl Opt 52: 2374–2384.
[29]
Hoffman RM (1999) Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17: 343–359.
[30]
Killion JJ, Radinsky R, Fidler IJ (1998) Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer and Metastasis Reviews 17: 279–284.
[31]
Hu H, Liu J, Yao L, Yin J, Su N, et al. Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model. Oncol Rep 27: 1937–1943.
[32]
Virostko J, Powers AC, Jansen ED (2007) Validation of luminescent source reconstruction using single-view spectrally resolved bioluminescence images. Appl Opt 46: 2540–2547.
[33]
Cheong SJ, Lee CM, Kim EM, Uhm TB, Jeong HJ, et al. (2011) Evaluation of the therapeutic efficacy of a VEGFR2-blocking antibody using sodium-iodide symporter molecular imaging in a tumor xenograft model. Nucl Med Biol 38: 93–101.
[34]
Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE, et al. (2000) Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia (New York, NY) 2: 491.
[35]
Xibo M, Zhaofei L, Xin Y, Qiujuan G, Shouping Z, et al. (2011) Dual-modality Monitoring of Tumor Response to Cyclophosphamide Therapy in Mice with Bioluminescence Imaging and Small-animal Positron Emission Tomography. Molecular imaging 10: 278–283.
[36]
Han D, Yang X, Liu K, Qin C, Zhang B, et al. (2011) Efficient reconstruction method for L1 regularization in fluorescence molecular tomography. Appl Opt 49: 6930–6937.
[37]
Han D, Tian J, Zhu S, Feng J, Qin C, et al. (2011) A fast reconstruction algorithm for fluorescence molecular tomography with sparsity regularization. Opt Express 18: 8630–8646.
